Clove

Clove's essential oil is dominated by eugenol (≈79% of volatile oil), which exerts antimicrobial, analgesic, and antioxidant effects through free radical scavenging, membrane disruption, and enzyme inhibition, while the chromones biflorin and isobiflorin suppress inflammatory signaling via STAT1 inactivation. In vitro antimicrobial assays demonstrate 93–100% microbial inhibition at eugenol concentrations as low as 0.06%, supporting its longstanding role as a dental antiseptic and analgesic in Indonesian Jamu and global ethnomedicine.

Origin & History

Syzygium aromaticum is indigenous to the North Moluccas (Maluku Islands) of Indonesia, where it thrives in tropical, humid climates with rich volcanic soils at low to moderate elevations. The tree is an evergreen of the Myrtaceae family, cultivated widely across Indonesia, Madagascar, Tanzania (Zanzibar), Sri Lanka, and India for its aromatic dried flower buds. Traditional cultivation relies on hand-harvesting of unopened buds before flowering, which are then sun-dried to yield the commercial spice.

Historical & Cultural Context

Clove has been traded as a precious commodity for over 2,000 years, originating in the Maluku Islands of Indonesia and reaching ancient Rome, China, and the Arab world via spice trade routes as early as the Han Dynasty (206 BCE–220 CE), when courtiers reportedly held cloves in their mouths to freshen breath before addressing the emperor. In Indonesian Jamu—the archipelago's traditional herbal medicine system—clove buds and their essential oil have been central ingredients for dental pain relief, antisepsis, and respiratory complaints for centuries, and clove remains one of Indonesia's most economically significant agricultural exports. Ayurvedic medicine classifies clove (Lavanga) as a warming, pungent herb used to kindle digestive fire (agni), relieve vomiting, and address respiratory congestion, while Traditional Chinese Medicine employs it (Ding Xiang) to warm the middle burner, descend rebellious qi, and treat hiccup and nausea. The 15th-century European spice trade, during which cloves commanded prices equivalent to gold by weight, drove the Age of Exploration and was a proximate cause of Portuguese, Dutch, and Spanish colonization of the Maluku Islands.

Health Benefits

- **Dental Analgesia and Oral Antisepsis**: Eugenol (≈79% of clove EO) reversibly blocks voltage-gated sodium channels and disrupts bacterial cell membranes, producing local anesthetic and broad-spectrum antimicrobial effects that underpin clove's use for toothache relief and oral infections in Jamu and Western dentistry.
- **Antioxidant Activity**: Eugenol and phenolic compounds including ellagic acid, kaempferol, and rhamnetin donate hydrogen atoms to neutralize reactive oxygen species and upregulate endogenous antioxidant enzymes, with clove ranking among the highest-ORAC botanicals measured in vitro.
- **Anti-Inflammatory Effects**: The chromones biflorin and isobiflorin inactivate STAT1 in LPS-stimulated macrophages, reducing pro-inflammatory cytokine cascades; β-caryophyllene (≈11.6% of EO) additionally acts as a selective CB2 receptor agonist to modulate peripheral inflammation.
- **Antimicrobial and Antifungal Action**: Clove EO at 0.04–0.06% concentrations achieves 93–100% inhibition of tested bacterial strains in vitro through membrane permeabilization and inhibition of bacterial efflux pumps and ATPase activity, with activity extending to Candida species and dermatophytes.
- **Hypoglycemic Potential**: Oleanolic acid and maslinic acid (triterpenoids) inhibit α-glucosidase and improve insulin receptor sensitivity in preclinical models, suggesting a role in postprandial glucose modulation, though human dose-response data remain limited.
- **Analgesic and Neuroprotective Properties**: Eugenol modulates TRPV1 (transient receptor potential vanilloid 1) channels and suppresses prostaglandin synthesis via COX inhibition, reducing pain signaling; preclinical rodent models indicate neuroprotective effects against oxidative neuronal damage.
- **Antiulcer and Gastroprotective Activity**: Eugenol reduces gastric acid secretion and promotes mucus production by modulating H+/K+-ATPase activity and upregulating prostaglandin E2, with preclinical gastric ulcer models showing significant lesion reduction, though clinical translation is unconfirmed.

How It Works

Eugenol, constituting approximately 79% of clove essential oil, exerts its primary pharmacological effects through multiple concurrent pathways: it scavenges free radicals via its phenolic hydroxyl group, inhibits cyclooxygenase (COX-1 and COX-2) enzymes to reduce prostaglandin synthesis, and disrupts microbial membrane integrity by intercalating into phospholipid bilayers, compromising membrane potential and ion transport. The sesquiterpene β-caryophyllene (≈11.6% of EO) selectively binds cannabinoid receptor type 2 (CB2) without psychoactivity, attenuating NF-κB-mediated inflammatory gene transcription in immune cells. Biflorin and isobiflorin, chromone glycosides unique to Syzygium species, specifically inactivate STAT1 phosphorylation in LPS-stimulated macrophages, reducing interferon-γ-driven inflammatory amplification. Triterpenoids including oleanolic acid and maslinic acid competitively inhibit intestinal α-glucosidase and may enhance GLUT4 translocation, contributing to the observed hypoglycemic activity in preclinical assays.

Scientific Research

The evidence base for Syzygium aromaticum is predominantly preclinical, comprising in vitro antimicrobial assays, cell-culture inflammatory models, and rodent studies, with no well-powered randomized controlled trials identified in the current literature. GC-MS characterization studies consistently confirm eugenol dominance (70–80% of EO) and establish antimicrobial minimum inhibitory concentrations, but these in vitro findings have not been systematically translated to human clinical endpoints. The anti-inflammatory activity of biflorin and isobiflorin via STAT1 inactivation has been demonstrated in macrophage cell lines, and molecular docking analyses report binding affinities (e.g., α-farnesene at −7.2 to −7.4 kcal/mol to relevant targets), but these computational predictions require experimental and clinical validation. Eugenol's use as a dental analgesic has the longest clinical precedent and is recognized in pharmacopoeial monographs, yet quantified human trial data on sample sizes, effect sizes, and standardized dosing regimens remain sparse in the peer-reviewed literature.

Clinical Summary

No large-scale randomized controlled trials specifically examining Syzygium aromaticum supplementation in human subjects were identified in the current evidence review, leaving clinical conclusions heavily dependent on extrapolation from preclinical and in vitro data. The most clinically grounded application is dental analgesia and antisepsis using eugenol-containing preparations, which have long-standing pharmacopoeial recognition and are embedded in standard dental practice (e.g., zinc oxide-eugenol cements), though formal RCT quantification of effect sizes in these settings is limited. Preclinical hypoglycemic and anti-inflammatory outcomes are promising but lack Phase II or Phase III human trial confirmation with defined endpoints, comparators, or adverse event monitoring. Confidence in clove's bioactive effects is moderate for antimicrobial and antioxidant properties based on consistent in vitro replication, but low-to-preliminary for systemic benefits such as neuroprotection, anti-obesity, and immunomodulation without supporting human data.

Nutritional Profile

Dried clove buds provide approximately 274 kcal/100 g, with macronutrient composition of roughly 13 g protein, 13 g fat (including sterols campesterol and stigmasterol), and 66 g total carbohydrate including significant dietary fiber (~34 g). Micronutrient content is notable for manganese (≈60 mg/100 g, >2,600% DV), vitamin K (~142 µg/100 g), vitamin C (~80 mg/100 g), magnesium (~259 mg/100 g), calcium (~632 mg/100 g), and iron (~11.8 mg/100 g), though these concentrations are relevant only at supplemental rather than typical culinary intakes. The phytochemical matrix includes essential oil (8.9% of dry weight), dominated by eugenol (79.21%), β-caryophyllene (11.60%), and eugenol acetate (6.27%), alongside flavonoids (kaempferol, rhamnetin, eugenitin), tannins (ellagic acid, bicornin), triterpenoids (oleanolic acid, maslinic acid), and chromones (biflorin, isobiflorin). Eugenol bioavailability is enhanced by lipophilic formulations and reduced by high-fiber matrices; the compound undergoes extensive hepatic conjugation via glucuronidation and sulfation, yielding metabolites excreted renally.

Preparation & Dosage

- **Whole Dried Buds (Culinary/Traditional)**: 1–3 g of ground clove buds per day as a culinary spice, consistent with historical Jamu and Ayurvedic practice; no established therapeutic ceiling at this dose.
- **Essential Oil (Topical/Dental)**: 0.5–1% eugenol-standardized clove EO diluted in a carrier oil for topical dental application; used neat (undiluted) only by dental professionals due to mucosal irritation risk.
- **Standardized Extract (Oral Supplement)**: Hydroalcoholic or ethanolic extracts standardized to ≥70% eugenol content, with experimental doses of 125–500 mg/day used in preclinical-extrapolated human protocols; no formally established human therapeutic dose.
- **Essential Oil (Antimicrobial/In Vitro Reference)**: Concentrations of 0.04–0.06% demonstrate 93–100% microbial inhibition in vitro; direct translation to oral dosing equivalents has not been established.
- **Steam-Distilled EO (Aromatherapy)**: Diffusion at 2–5 drops per 100 mL water for inhalation applications; internal use requires professional supervision.
- **Standardization Note**: European Pharmacopoeia requires >7.4% EO yield from dried buds; quality products should meet this specification and confirm eugenol content ≥75% by GC analysis.

Synergy & Pairings

Eugenol demonstrates additive-to-synergistic antimicrobial activity when combined with thymol (from Thymus vulgaris) or carvacrol (from Origanum vulgare), as these compounds attack bacterial membranes through complementary mechanisms—eugenol via lipid bilayer intercalation and thymol/carvacrol via disruption of the proton motive force—producing lower combined MICs than either agent alone. β-Caryophyllene's CB2 agonism may synergize with CBD (cannabidiol) for anti-inflammatory applications, as both compounds modulate the endocannabinoid system through distinct binding mechanisms, a combination explored in topical pain formulations. In Jamu tradition, clove is frequently combined with ginger (Zingiber officinale) and black pepper (Piper nigrum), where piperine from black pepper may enhance eugenol bioavailability by inhibiting glucuronidation, and ginger's gingerols contribute complementary COX-inhibitory and gastroprotective activity.

Safety & Interactions

Clove essential oil applied undiluted to oral mucosa can cause chemical burns, contact dermatitis, and mucosal necrosis; topical concentrations above 1% eugenol are associated with irritation and should be used only under professional dental supervision. Eugenol inhibits platelet aggregation through thromboxane A2 suppression and may potentiate the effects of anticoagulant and antiplatelet drugs (warfarin, clopidogrel, aspirin), increasing bleeding risk; it also inhibits CYP2C9 and CYP3A4 isoenzymes in vitro, raising theoretical concerns for interactions with drugs metabolized by these pathways, though clinical significance at typical dietary doses is unconfirmed. Ingestion of large quantities of clove oil (>5 mL) has caused acute hepatotoxicity, seizures, and metabolic acidosis in case reports, particularly in children; clove oil is considered unsafe for internal use in infants and young children. Pregnancy and lactation safety is unestablished beyond culinary use; high-dose eugenol exhibits uterotonic properties in animal models, and supplemental clove preparations should be avoided during pregnancy without medical supervision.